Archive: Company News
Company News: Curetis and MGI Advance Strategic Partnership in NGS-Based Molecular Microbiology
— Inked new collaboration and commercialization deals with MGI to leverage Curetis´ sample preparation technology
— Enabling short-term commercialization of NGS-based molecular microbiology
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that the Company is advancing its strategic alliance in NGS-based infectious disease testing. To this end, Curetis has signed a Supply and Authorization Agreement as well as a further R&D Collaboration and Service Agreement with MGI, a fully-owned subsidiary of BGI Group, one of the world’s leading genome sequencing centers headquartered in Shenzhen, Guangdong, P. R. China.
Company News: Curetis Expects Near-Term FDA Decision on De Novo Request
– Review of the Unyvero System and Lower Respiratory Tract (LRT) Cartridge is nearing completion
– U.S. commercial team and operational infrastructure in place
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today provided a status update on the FDA De Novo filing for the Company’s Unyvero System and LRT Cartridge for the diagnosis of lower respiratory tract infections.
Company News: BioNTech Secures USD 270 Million in Series A Financing
BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced it has completed a USD 270 million Series A round of financing. The Company previously completed a seed round fundraising in 2008 concurrent with its founding.
Company News: ISA Pharmaceuticals to Present at the Biotech Showcase™ Annual Conference 2018
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that it will present at Biotech Showcase™ 2018, to be held January 8–10 at the Hilton San Francisco Union Square.